Quick Dispatch:
Your triumph-1 retatrutide TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes — with continued loss to 30.3% at 104 weeks in… | orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your triumph-1 retatrutide TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes — with continued loss to 30.3% at 104 weeks in… | ships.
Need Help?
Questions about triumph-1 retatrutide TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes — with continued loss to 30.3% at 104 weeks in… |, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for triumph-1 retatrutide TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes — with continued loss to 30.3% at 104 weeks in… | in your area.
Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:
24.13
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism
26.35
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)
27.84
Eli Lilly Retatrutide: 28% Weight Loss in Phase 3 Results
29.70
TRIUMPH-1 trial results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to bariatric surgery
24.00
Retatrutide produces up to 30.3% weight loss in Phase 3 trial
26.70
⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “overweight”
25.21
30074-7/asset/b2323164-dbfd-44d8-85e5-f8d38f04a643/main.assets/gr2_lrg.jpg)
